News: ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

8.17EUR
6:20am EDT
Price Change (% chg)

€-0.34 (-4.02%)
Prev Close
€8.51
Open
€8.51
Day's High
€8.59
Day's Low
€8.00
Volume
102,876
Avg. Vol
214,255
52-wk High
€32.83
52-wk Low
€8.00

Search Stocks
Select another date:

Thu, Jul 3 2014

BRIEF-Thrombogenics NV says Jetrea gains approval in Singapore

* Jetrea(r) (ocriplasmin) has been approved in singapore for treatment of adults with vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns

BRIEF-Thrombogenics' drug Jetrea gains first Latin American approval in Uruguay

* Thrombogenics' Jetrea gains first latin american approval in uruguay

BUZZ-ThromboGenics collapses after chooses independence

** Shares in ThromboGenics drop to a five-year low after the Belgian biotech firm rules out a sale of its business, concluding that it plans to remain a stand-alone company, while seeking a partner to boost stalled sales of its eye drug in the United States.

ThromboGenics rules out sale, CFO quits

BRUSSELS, June 24 - Belgian biotech company ThromboGenics said on Tuesday that it had ruled out putting itself up for sale and that its chief financial officer had resigned, a day after its shares fell to a near three-year low.

BRIEF-ThromboGenics to stay as stand-alone company, CFO to quit

* Company will provide a further update at time of its 2014 half year reporting on August 28

BRIEF-Thrombogenics NV says Jetrea drug receives approval in Malaysia

* Thrombogenics' Jetrea gains first Asian approval in Malaysia

BRIEF-Thrombogenics says Jetrea approved in Switzerland

BRUSSELS, March 18 - Thrombogenics: * Thrombogenics JETREA approved in Switzerland for the treatment of vitreomacular traction

ThromboGenics reports slowdown of sales of main drug Jetrea

BRUSSELS - Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of 2013.

ThromboGenics reports slowdown of sales of main drug Jetrea

BRUSSELS, March 18 - Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of 2013.

BRIEF-Thrombogenics gets 3 mln euros grant for diabetic macular edema research

BRUSSELS, March 10 - ThromboGenics NV : * Awarded 3 million euros IWT grant to support research new therapeutic for diabetic macular edema

Select another date:
Search Stocks